Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
Dr. John Cush RheumNow
1 week 2 days ago
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p
Dr. John Cush RheumNow
1 week 2 days ago
SLE Pipeline of New Therapies
Dr. Andrea Fava, EULAR 2026 in London.
https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF
Dr. John Cush RheumNow
1 week 2 days ago
Treat to Target Works in Elderly Onset RA
Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London
https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP
Dr. John Cush RheumNow
1 week 2 days ago
Digital Platforms and AI
Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf
Dr. John Cush RheumNow
1 week 2 days ago
Digital Patient Education in RA
Dr. Bella Mehta reviews abstract OP005-HPR presented in London at EULAR 2026
https://t.co/Wj8omKJTNx. https://t.co/h13p54BAHs
Dr. John Cush RheumNow
1 week 2 days ago
Understanding Comorbidities in RMD
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush RheumNow
1 week 2 days ago
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
Dr. John Cush RheumNow
1 week 2 days ago
Day 1 Report from EULAR 2026
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush RheumNow
1 week 2 days ago
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
